Position as of September 30, 2020 has changed from December 31, 2019 as follows; Assets (Mil . Baht) Total Liabilities & Shareholders' Equity (Mil. Baht) Cash and cash equivalents Total other current

amount of 90 million baht while GSTEL is unable to secure external funding sources. In addition, GJS has sufficient cash flows and liquidity to support the short-term loan to GSTEL without collateral

raw material and cash conversion cost. On a YoY basis, the Company and subsidiary’s total net loss increased by Baht 666 million or 91% while total revenue from sales and services increased by Baht

EBITDA 609 2,347 Group Net Profit (Loss) (2,358) (388) HRC Sales (k tons) 1,450 1,381 HRC Production Volume (k tons) 1,438 1,429 HRC Average Selling Price (Bht/Ton) 20,662 18,529 HRC Cash Margin (Bht/Ton

. Financial Position Analysis Unit : MB As at 31 March 2019 As at 31 December 2018 Change MB % Cash and cash equivalents 94.15 159.65 (65.50) (41.03) Current investment 156.25 156.04 0.21 0.13 Inventories

reducing the deposit limit in cash or cash equivalent of any specific issuer (single entity limit) from the previous 20 percent to 10 percent, and (2) requiring more disclosure in the fact sheet of

declared as the “Year of Shift”. It is the opportunity for the organization, high-ranking executives and staff to revise the business model in order for the organization to achieve stable growth and the goal

%, compared with the same period of the last year. As a result of operating profit that significant growth and finance costs are very low level because of the stable financial position. DOD BIOTECH PUBLIC

in Q4/2018 continuously grew. Export-oriented manufacturing businesses continuously expanded but domestic-oriented manufacturing was rather stable as slow recovery of private consumption and high

was offset by an increase in cash from Bt9,067mn to Bt19,637mn at the end of FY19, which mainly contributed from operating activities. Inventories at the end of FY19 was Bt4,828.5mn, increasing 26% YoY